AstraZeneca (LON:AZN) Receives Buy Rating from Berenberg Bank

Berenberg Bank reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Monday,Digital Look reports. Berenberg Bank currently has a GBX 140 ($1.75) price target on the biopharmaceutical company’s stock.

A number of other brokerages also recently weighed in on AZN. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. JPMorgan Chase & Co. reiterated an “overweight” rating and set a £140 ($175.15) price target on shares of AstraZeneca in a research report on Friday, November 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 7,935.67 ($99.28).

AstraZeneca Stock Down 0.4 %

LON AZN traded down GBX 44 ($0.55) during mid-day trading on Monday, hitting £106.68 ($133.47). The company’s stock had a trading volume of 1,807,867 shares, compared to its average volume of 2,434,591. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. The company’s 50 day simple moving average is £105.36 and its 200 day simple moving average is £116.94. The firm has a market capitalization of £165.35 billion, a price-to-earnings ratio of 3,386.67, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a twelve month low of GBX 9,461 ($118.37) and a twelve month high of £133.88 ($167.50).

Insider Buying and Selling at AstraZeneca

In other news, insider Pascal Soriot bought 20,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The shares were purchased at an average price of £102.03 ($127.65) per share, for a total transaction of £2,040,600 ($2,552,983.86). Also, insider Tony Mok acquired 1,500 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average price of £126.80 ($158.64) per share, with a total value of £190,200 ($237,958.21). Insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.